All Articles
The Return On Investment of Better CDx Planning Based on Early PD-L1 Observations in NSCLC

The Return On Investment of Better CDx Planning Based on Early PD-L1 Observations in NSCLC

4 April, 2019

Sanna Jousi of Diaceutics assesses the financial benefits of integrating the planning, analytical and action steps for successful development and commercialization of testing into targeted therapies.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny